REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 532.6B
Enterprise Value 330.52B
Trailing P/E 16.49
Forward P/E 111.83
PEG Ratio (5 yr expected) 12.01
Price/Sales (ttm)4.51
Price/Book (mrq)3.33
Enterprise Value/Revenue 34.22
Enterprise Value/EBITDA 613.15

Trading Information

Stock Price History

Beta (3Y Monthly) 0.85
52-Week Change 3-21.80%
S&P500 52-Week Change 3-0.33%
52 Week High 3442.00
52 Week Low 3287.66
50-Day Moving Average 3303.56
200-Day Moving Average 3350.73

Share Statistics

Avg Vol (3 month) 3803.01k
Avg Vol (10 day) 3622.28k
Shares Outstanding 5107.73M
Float 81.22M
% Held by Insiders 124.61%
% Held by Institutions 172.68%
Shares Short (Jul 31, 2019) 42.35M
Short Ratio (Jul 31, 2019) 42.94
Short % of Float (Jul 31, 2019) 42.95%
Short % of Shares Outstanding (Jul 31, 2019) 42.14%
Shares Short (prior month Jun 28, 2019) 42.29M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 28.59%
Operating Margin (ttm)29.58%

Management Effectiveness

Return on Assets (ttm)11.57%
Return on Equity (ttm)24.43%

Income Statement

Revenue (ttm)7.24B
Revenue Per Share (ttm)66.64
Quarterly Revenue Growth (yoy)20.30%
Gross Profit (ttm)4.09B
EBITDA 2.32B
Net Income Avi to Common (ttm)2.07B
Diluted EPS (ttm)18.00
Quarterly Earnings Growth (yoy)-65.00%

Balance Sheet

Total Cash (mrq)2.67B
Total Cash Per Share (mrq)24.4
Total Debt (mrq)711.3M
Total Debt/Equity (mrq)7.29
Current Ratio (mrq)3.88
Book Value Per Share (mrq)89.25

Cash Flow Statement

Operating Cash Flow (ttm)2.27B
Levered Free Cash Flow (ttm)1.12B